Document outlines potential regulatory path for federal cannabis legalization and mentions DEA/FDA actions under Attorney General Sessions

Document outlines potential regulatory path for federal cannabis legalization and mentions DEA/FDA actions under Attorney General Sessions The passage provides a general overview of how the DEA and FDA could enable federal cannabis legalization without a change in law and references a 2016 DEA policy and the current DOJ leadership. It hints at possible regulatory shifts but lacks concrete names, dates, transactions, or evidence of misconduct, limiting its investigative utility. However, it does involve high‑level agencies and the Attorney General, giving it moderate relevance for follow‑up on policy influence and lobbying. Key insights: DEA can register manufacturers to produce medical cannabis under the CSA.; FDA can approve cannabis‑derived drugs under the FD&C Act.; A 2016 DEA policy aimed to increase the number of registered cannabis cultivators.